Small bowel obstruction due to metastatic colon cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.

Original languageEnglish (US)
JournalAnti-Cancer Drugs
Volume20
Issue numberSPEC. ISS. 2
DOIs
StatePublished - May 2009

Fingerprint

Colonic Neoplasms
Leucovorin
Fluorouracil
Colorectal Neoplasms
Monoclonal Antibodies
Survival
Neoplasms
Therapeutics

Keywords

  • Avastin
  • Multi-modality therapy
  • XELIRI

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Small bowel obstruction due to metastatic colon cancer. / Huerta, Sergio; Li, Hsiao C.

In: Anti-Cancer Drugs, Vol. 20, No. SPEC. ISS. 2, 05.2009.

Research output: Contribution to journalArticle

@article{4e00e4db9c744b8492fa0fbb3f4e1ad0,
title = "Small bowel obstruction due to metastatic colon cancer",
abstract = "Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100{\%} in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.",
keywords = "Avastin, Multi-modality therapy, XELIRI",
author = "Sergio Huerta and Li, {Hsiao C.}",
year = "2009",
month = "5",
doi = "10.1097/01.cad.0000349758.87244.02",
language = "English (US)",
volume = "20",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "SPEC. ISS. 2",

}

TY - JOUR

T1 - Small bowel obstruction due to metastatic colon cancer

AU - Huerta, Sergio

AU - Li, Hsiao C.

PY - 2009/5

Y1 - 2009/5

N2 - Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.

AB - Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.

KW - Avastin

KW - Multi-modality therapy

KW - XELIRI

UR - http://www.scopus.com/inward/record.url?scp=68049110611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049110611&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000349758.87244.02

DO - 10.1097/01.cad.0000349758.87244.02

M3 - Article

C2 - 19352104

AN - SCOPUS:68049110611

VL - 20

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - SPEC. ISS. 2

ER -